A140610 Stock Overview
A biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ensol Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,300.00 |
| 52 Week High | ₩13,000.00 |
| 52 Week Low | ₩2,800.00 |
| Beta | 0 |
| 11 Month Change | 59.60% |
| 3 Month Change | 68.91% |
| 1 Year Change | 4.73% |
| 33 Year Change | -30.25% |
| 5 Year Change | 39.51% |
| Change since IPO | -10.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| A140610 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.7% | 4.3% | 1.4% |
| 1Y | 4.7% | 43.9% | 2.8% |
Return vs Industry: A140610 underperformed the KR Biotechs industry which returned 43.9% over the past year.
Return vs Market: A140610 exceeded the KR Market which returned 2.8% over the past year.
Price Volatility
| A140610 volatility | |
|---|---|
| A140610 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A140610's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A140610's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | n/a | ensolbio.co.kr |
Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for the treatment of triple negative breast cancer; Moriah 1000 that is in pre-clinical stage for the treatment of Alzheimer’s disease; Shiloah 1000, which is in pre-clinical stage for the treatment of type 1 diabetes; Allose 1000 that is in pre-clinical stage for the treatment of atopic dermatitis; EAD200, a drug for animal anti-cancer drug; and EAD300 for the treatment of porcine reproductive and respiratory syndrome.
Ensol Biosciences Inc. Fundamentals Summary
| A140610 fundamental statistics | |
|---|---|
| Market cap | ₩97.38b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A140610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140610 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A140610 perform over the long term?
See historical performance and comparison